Osi Pharmaceuticals, Inc.

Other

Phosphonics Limited

Robin Wilkes

Neil Anthony Pegg

Colin Peter Sambrook Smith

Matthew Cox

Andrew Philip Crew

Hanqing Dong

Radoslaw Laufer

Bijoy Panicker

An-Hu Li

Mark Joseph Mulvihill

Douglas S Werner

Arno G Steinig

Shazia Sadiq

Han-Qing Dong

Yingchuan Sun

Kenneth W Foreman

Qinghua Weng

Anthony Innocenzo Nigro

Jonathan G Williams

Jason Bloxham

Cara Cesario

John Kitchin

Kathryn M Stolz

Oscar Barba

William Gattrell

Paul M Murray

Amo G Steinig

Saleh Ahmed

Graham Dawson

Imaad Saba

Don Smyth

Christopher North

Lifu Ma

Patricia Anne Beck

Paula Tavares

Kenneth (‘Ken’) Foreman

Qinghua (‘Felix’) Weng

Lydia Saroglou

A process for the selective removal of a component from a liquid phase and subsequently returning the component to a liquid phase is disclosed. A novel compound of formula (I) [SUP]-[[L]-[G]]a (I) in which L is a linking group, G is an aryl group having a leaving group LG selected from Cl, Br, I, sulfonate such as triflate, a diazo group, a nitrile, an ester and an alkoxy group and substituent Q is selected from H, NR2, OR, CO2R, F, Cl, NO2 CN and SUP is a support having a plurality of groups -[L]-[G] bound to the support is contacted with the liquid phase to bind the component to the compound I thereby forming a captured component which is separated from and may be returned to the liquid phase. The compound I is especially useful in binding homogeneous catalysts to remove it from a reaction medium and selectively returning the catalyst to the reaction medium at a later stage. The compound is particularly useful for cross-coupling reactions, for example in Suzuki reactions.

Process for the removal and return of a catalyst to a liquid phase medium

Substituted pyrrolo[2.3-B]pyridines

Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Qand Rare defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.

Imidazopyrazine tyrosine kinase inhibitors

Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of tumors. Combinatorial libraries composed of compounds represented by Formula (I) or benzimidazole compounds represented by Formula (II): are useful in providing compounds to assay for such therapeutically useful compounds.

N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library

Growing community of inventors

Oxford, United Kingdom

Robin Wilkes